Litcius/Paper detail

Dapagliflozin attenuates AKI to CKD transition in diabetes by activating SIRT3/PGC1-α signaling and alleviating aberrant metabolic reprogramming

Huimin Li, Yao Xia, Hongchu Zha, Yafei Zhang, Lang Shi, Jia‐Yi Wang, Hua Huang, Ruchi Yue, Bin Hu, Jiefu Zhu, Zhixia Song

2024Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease13 citationsDOI

Topics & Concepts

DapagliflozinMedicineKidney diseaseDiabetes mellitusReprogrammingAcute kidney injurySIRT3Internal medicineType 2 diabetesEndocrinologyBiologyCellGeneGeneticsAcetylationBiochemistrySirtuinNeurological and metabolic disordersAcute Kidney Injury ResearchHyperglycemia and glycemic control in critically ill and hospitalized patients
Dapagliflozin attenuates AKI to CKD transition in diabetes by activating SIRT3/PGC1-α signaling and alleviating aberrant metabolic reprogramming | Litcius